Rubius Therapeutics (RUBY) Issues Strategic Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. GPRK
6. SCHW
7. TRV
8. TFC
9. NVDA
10. POLYCAB:IN

Go back to Rubius Therapeutics (RUBY) Issues Strategic Update

Rubius Therapeutics Announces Strategic Update

September 13, 2022 7:00 AM EDT

Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform

Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023

Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors

Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT

CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer... More